Ketamine pharmacotherapy for major depressive disorder: A narrative review - PubMed
5 hours ago
- #Ketamine
- #Pharmacotherapy
- #Major Depressive Disorder
- Ketamine pharmacotherapy is a novel treatment for major depressive disorder (MDD) and treatment-resistant depression (TRD).
- The FDA has approved ketamine for MDD with suicidal ideation or behavior.
- Ketamine's mechanisms include NMDA receptor antagonism and AMPA-activated glutamate surge, promoting synaptogenesis and neuroplasticity.
- Common adverse effects include dissociation, sedation, and hypertension.
- Ketamine interacts with benzodiazepines, lamotrigine, antipsychotics, and CYP inhibitors like SSRIs.
- IV and intranasal esketamine show mixed-to-positive antidepressant effects in studies.
- Comparative studies indicate ketamine's non-inferiority to other treatments like ECT, pharmacotherapy, and TMS.
- Future research may focus on predictive markers, novel therapeutics, and broader applications.